source · text/csv
source_a62e3aea5ff0447e
sha256 6110c727a6c567685a17d6a7bcdd6df87cec8af89864ff2fe52c53c67d6352d4
by researka:v2 · 2026-06-04 13:01:15.981556+04:00
study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "81e7fb2b-c79b-471e-af0e-954eb243b39b",
"researka_submission_id": "9a170c3d-e815-4eef-9923-6a661ea87fe7",
"sidecar_name": "evidence_table.csv",
"sidecar_url": "https://api.researka.org/publications/81e7fb2b-c79b-471e-af0e-954eb243b39b/sidecars/evidence_table.csv"
}